Invanz Sandbox
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
<scene name='PageName/SceneName/Version#' target='StructureAppletName'>Text Displayed On Page</scene> | <scene name='PageName/SceneName/Version#' target='StructureAppletName'>Text Displayed On Page</scene> | ||
| + | |||
| + | <StructureSection load='4QU3' size='340' side='right' caption='Beta-lactamase Ges-2 Acyl Enzyme Complex(PDB code [[4QU3]])'> | ||
== Function == | == Function == | ||
Invanz is used to treat a range of bacterial infections caused by Gram positive and Gram negative bacteria as well as a range of both aerobic and anaerobic bacteria. Invanz works by inhibiting cell wall synthesis via binding to penicillin binding proteins (PBPs). Invanz is stable against hydrolysis from many beta-lactamases including penicillinases and cephalosporinases, but is unstable against metallo-beta-lactamases <ref name="merck" />. Beta-lactamases are secreted by bacteria to provide resistance to antibiotics; however, Invanz is relatively unaffected by these beta-lactamases and thus is an effective treatment for various bacterial infections <ref>PMID: 25561890</ref>. The unique structural features of Invanz equip this drug with some of the widest spectrum and most potent antimicrobial activity of carbapenem antibiotics today <ref>PMID: 12951340</ref>. | Invanz is used to treat a range of bacterial infections caused by Gram positive and Gram negative bacteria as well as a range of both aerobic and anaerobic bacteria. Invanz works by inhibiting cell wall synthesis via binding to penicillin binding proteins (PBPs). Invanz is stable against hydrolysis from many beta-lactamases including penicillinases and cephalosporinases, but is unstable against metallo-beta-lactamases <ref name="merck" />. Beta-lactamases are secreted by bacteria to provide resistance to antibiotics; however, Invanz is relatively unaffected by these beta-lactamases and thus is an effective treatment for various bacterial infections <ref>PMID: 25561890</ref>. The unique structural features of Invanz equip this drug with some of the widest spectrum and most potent antimicrobial activity of carbapenem antibiotics today <ref>PMID: 12951340</ref>. | ||
| - | |||
== Structural highlights == | == Structural highlights == | ||
| Line 13: | Line 14: | ||
There are various structural features of Invanz that make make administration of the drug easy. Older carbapenems required patients to take a dehydropeptidase-1 (DHP-1) inhibitor since the DHAP enzyme found in the human renal system could interfere with the action of the carbapenem by degrading the antibiotic <ref name="Invanz1" />. Invanz is a unique antibiotic because it has a 1-beta-methyl substituent that shields the beta-lactam carbonyl from DHP-1 degradation <ref name="hammond">...</ref>. The meta-substituted benzoic acid substituent increases the molecular weight and makes the drug more soluble in nonpolar solvents. Additionally, the carboxylic acid substituent becomes ionized at physiological pH, so the ertapenem has a net negative charge. Increased solubility in non polar solvents and the net negative charge allows the drug to bind human plasma proteins with an extended half-life in the blood stream, and thus the drug only has to be administered once daily <ref name="hammond" />. Invanz largely travels in the bloodstream bound to the human plasma protein albumin <ref name="merck" />. | There are various structural features of Invanz that make make administration of the drug easy. Older carbapenems required patients to take a dehydropeptidase-1 (DHP-1) inhibitor since the DHAP enzyme found in the human renal system could interfere with the action of the carbapenem by degrading the antibiotic <ref name="Invanz1" />. Invanz is a unique antibiotic because it has a 1-beta-methyl substituent that shields the beta-lactam carbonyl from DHP-1 degradation <ref name="hammond">...</ref>. The meta-substituted benzoic acid substituent increases the molecular weight and makes the drug more soluble in nonpolar solvents. Additionally, the carboxylic acid substituent becomes ionized at physiological pH, so the ertapenem has a net negative charge. Increased solubility in non polar solvents and the net negative charge allows the drug to bind human plasma proteins with an extended half-life in the blood stream, and thus the drug only has to be administered once daily <ref name="hammond" />. Invanz largely travels in the bloodstream bound to the human plasma protein albumin <ref name="merck" />. | ||
| - | |||
== Microbial Action == | == Microbial Action == | ||
Revision as of 13:10, 26 November 2016
Invanz (Ertapenem) is a 1-beta-methyl carbapenem antibiotic that is designed to treat multi drug resistant bacterial infections such as intra-abdominal infections, skin and skin suture infections, community-acquired pneumonia, complicated urinary tract infections including pyelonephritis, acute pelvic infections, and can be used as a prophylactic measure prior to colorectal surgery. Invanz is an injectable antibiotic that can be administered intramuscularly [1][2].
|
| |||||||||||
